KR20050120663A - 장기간 작용하는 생물학적 활동 컨쥬게이트들 - Google Patents

장기간 작용하는 생물학적 활동 컨쥬게이트들 Download PDF

Info

Publication number
KR20050120663A
KR20050120663A KR1020057017965A KR20057017965A KR20050120663A KR 20050120663 A KR20050120663 A KR 20050120663A KR 1020057017965 A KR1020057017965 A KR 1020057017965A KR 20057017965 A KR20057017965 A KR 20057017965A KR 20050120663 A KR20050120663 A KR 20050120663A
Authority
KR
South Korea
Prior art keywords
group
complex
xxx
alkyl
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057017965A
Other languages
English (en)
Korean (ko)
Inventor
아베라르도 실바
존 이 에릭슨
미첼 에이센스테트
엘레나 아포니나
세르게이 굴닉
Original Assignee
세쿠오이아 파마큐티컬스 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세쿠오이아 파마큐티컬스 인코오퍼레이티드 filed Critical 세쿠오이아 파마큐티컬스 인코오퍼레이티드
Publication of KR20050120663A publication Critical patent/KR20050120663A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020057017965A 2003-03-24 2004-03-24 장기간 작용하는 생물학적 활동 컨쥬게이트들 Withdrawn KR20050120663A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US45647203P 2003-03-24 2003-03-24
US60/456,472 2003-03-24
US45695203P 2003-03-25 2003-03-25
US60/456,952 2003-03-25
US51889203P 2003-11-10 2003-11-10
US60/518,892 2003-11-10

Publications (1)

Publication Number Publication Date
KR20050120663A true KR20050120663A (ko) 2005-12-22

Family

ID=33101274

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057017965A Withdrawn KR20050120663A (ko) 2003-03-24 2004-03-24 장기간 작용하는 생물학적 활동 컨쥬게이트들

Country Status (8)

Country Link
US (1) US20070207952A1 (enExample)
EP (1) EP1620120A4 (enExample)
JP (2) JP2006521361A (enExample)
KR (1) KR20050120663A (enExample)
AU (1) AU2004223829A1 (enExample)
CA (1) CA2520257A1 (enExample)
NZ (2) NZ567952A (enExample)
WO (1) WO2004085505A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
CA2518898A1 (en) * 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CA2559554A1 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
WO2006034455A2 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
JP2008534639A (ja) * 2005-04-08 2008-08-28 ロンザ ア−ゲ− Ｐｅｇ樹脂上におけるアルファ−ヘリックスのペプチド合成
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
CA2698981A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
GB201006038D0 (en) * 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
EA022983B1 (ru) 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Белки на основе структурного домена фибронектина, связывающие pcsk9
SG10201802116RA (en) 2010-08-18 2018-04-27 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
EP2758043A4 (en) 2011-08-17 2016-02-24 Dennis M Brown COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY APPLIED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL
US10201521B2 (en) 2012-01-20 2019-02-12 Del Mar Pharmaceuticals (Bc) Ltd. Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem and cancer stem cells including glioblastoma multiforme and medulloblastoma
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2013169600A1 (en) 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
SG11201700114WA (en) 2014-08-22 2017-02-27 Univ Nat Cheng Kung Disintegrin variants and pharmaceutical uses thereof
AU2018309724B2 (en) 2017-07-31 2024-07-18 The Trustees Of Indiana University Modified DDAH polypeptides comprising a pharmacokinetic enhancing moiety, improved pharmacology and their uses
CN111053892B (zh) * 2019-12-24 2023-11-17 山西锦波生物医药股份有限公司 一种广谱抗肠道病毒的蛋白类药物及其应用
CN117186187B (zh) * 2023-07-12 2024-05-31 中国医学科学院病原生物学研究所 一种抗呼吸道合胞病毒膜融合抑制剂及其药物用途
CN118409027B (zh) * 2024-07-02 2024-09-10 成都市食品检验研究院 一种食品中1-脱氧野尻霉素的含量检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164239B (it) * 1983-05-25 1987-04-08 Anic Spa Un retro-inverso analogo del decapeptide (5-14)dell'angiotensinogeno equino inibitore specifico della renina con elevata resistenza all'idrolisi enzimatica
IE873186L (en) * 1986-12-23 1988-06-23 Harvard College Renin inhibitors iv
EP0389535A1 (en) * 1987-10-26 1990-10-03 Warner-Lambert Company Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
EP1335938B1 (en) * 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
ES2242860T3 (es) * 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.

Also Published As

Publication number Publication date
NZ567952A (en) 2009-12-24
WO2004085505A3 (en) 2005-12-01
US20070207952A1 (en) 2007-09-06
AU2004223829A1 (en) 2004-10-07
WO2004085505A2 (en) 2004-10-07
CA2520257A1 (en) 2004-10-07
EP1620120A2 (en) 2006-02-01
NZ543122A (en) 2008-07-31
JP2011006419A (ja) 2011-01-13
EP1620120A4 (en) 2010-01-06
JP2006521361A (ja) 2006-09-21

Similar Documents

Publication Publication Date Title
KR20050120663A (ko) 장기간 작용하는 생물학적 활동 컨쥬게이트들
JP5907999B2 (ja) 長期間作用性ペプチド類似体のための組成物
JP5537431B2 (ja) ウイルス融合のインヒビターのコレステロール誘導体
US20120040891A1 (en) Hiv fusion inhibitor peptides with improved biological properties
JP2010209097A (ja) Ｈｉｖ感染のペプチド誘導体融合阻害剤
RU2741123C1 (ru) Липопептид для эффективного ингибирования вич, его производное, фармацевтическая композиция и их применение
US10487121B2 (en) D-peptide inhibitors of HIV entry and methods of use
JP2007529522A (ja) ＨＩＶｇｐ４１由来ペプチドの部位特異的化学修飾
US6664040B2 (en) Compositions and methods for delivery of a molecule into a cell
ZA200508190B (en) Long acting biologically active conjugates
CN104277113B (zh) 抑制hiv感染的二价多肽
US20030219451A1 (en) Stable helical C peptides and uses therefor
JPH0673092A (ja) レトロウイルスプロテアーゼ阻害剤
JP4332618B2 (ja) 抗ｈｉｖ剤
US20090088378A1 (en) Long lasting inhibitors of viral infection
TW200427697A (en) Pegylated t1249 polypeptide
CN118354791A (zh) 抑制导致新冠肺炎疾病的病毒sars-cov-2感染的肽
WO2012139519A1 (zh) 环肽及其医药用途
WO2008144590A2 (en) Long lasting modified antifusogenic peptide for preventing hiv infection
MXPA06009352A (es) Modificacion quimica especifica del sitio de peptidos derivados de gp 41 del vih

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050923

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid